The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report
Pancreatic squamous cell carcinoma (SCC) is a rare primary pancreatic malignancy with a poor prognosis. The median overall survival (OS) for metastatic setting is only 4 months and the optimal management remains poorly defined. In the present study, we report a 52-year-old female patient with stage...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.585983/full |
| _version_ | 1818957932311609344 |
|---|---|
| author | Xiaozhun Huang Chunling Wang Teng Ma Zhangkan Huang Houhong Zhou Lin Xu Renjie Zhang Jianjun Zhao Yefan Zhang Zhen Huang Lin Shao Yang Wang Fan Yang Xu Che Xu Che |
| author_facet | Xiaozhun Huang Chunling Wang Teng Ma Zhangkan Huang Houhong Zhou Lin Xu Renjie Zhang Jianjun Zhao Yefan Zhang Zhen Huang Lin Shao Yang Wang Fan Yang Xu Che Xu Che |
| author_sort | Xiaozhun Huang |
| collection | DOAJ |
| description | Pancreatic squamous cell carcinoma (SCC) is a rare primary pancreatic malignancy with a poor prognosis. The median overall survival (OS) for metastatic setting is only 4 months and the optimal management remains poorly defined. In the present study, we report a 52-year-old female patient with stage IV primary SCC of the pancreas harboring a deleteous BRCA2 somatic mutation. After 10 cycles of chemotherapy of cisplatin combined with nanoparticle albumin-bound paclitaxel, metastatic lesions in the liver and lymph nodes achieved radiographic complete responses and pancreatic lesion shrank from 5.7 to 1.5 cm in diameter. The patient subsequently underwent a posterior radical antegrade modular pancreatosplenectomy with R0 resection and residual liver lesions were also resected. After 3 months, a tumor relapsed in the liver. She was then treated with olaparib combined with pembrolizumab and achieved stable disease on the liver lesion. The patient eventually died from cerebral hemorrhage with a long OS of 21 months. Our case demonstrated a favorable clinical activity and survival advantage of the combined cisplatin and nanoparticle albumin-bound paclitaxel, which might serve as a therapeutic option for the patient with BRCA-mutant pancreatic SCC. |
| first_indexed | 2024-12-20T11:17:42Z |
| format | Article |
| id | doaj.art-19bd46deff264e84909af5fffe17a889 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-20T11:17:42Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-19bd46deff264e84909af5fffe17a8892022-12-21T19:42:33ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.585983585983The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case ReportXiaozhun Huang0Chunling Wang1Teng Ma2Zhangkan Huang3Houhong Zhou4Lin Xu5Renjie Zhang6Jianjun Zhao7Yefan Zhang8Zhen Huang9Lin Shao10Yang Wang11Fan Yang12Xu Che13Xu Che14Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hospital Acquired Infection Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Medicine, Burning Rock Biotech, Guangzhou, ChinaDepartment of Medicine, Burning Rock Biotech, Guangzhou, ChinaDepartment of Medicine, Burning Rock Biotech, Guangzhou, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Gastrointestinal and Pancreatic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaPancreatic squamous cell carcinoma (SCC) is a rare primary pancreatic malignancy with a poor prognosis. The median overall survival (OS) for metastatic setting is only 4 months and the optimal management remains poorly defined. In the present study, we report a 52-year-old female patient with stage IV primary SCC of the pancreas harboring a deleteous BRCA2 somatic mutation. After 10 cycles of chemotherapy of cisplatin combined with nanoparticle albumin-bound paclitaxel, metastatic lesions in the liver and lymph nodes achieved radiographic complete responses and pancreatic lesion shrank from 5.7 to 1.5 cm in diameter. The patient subsequently underwent a posterior radical antegrade modular pancreatosplenectomy with R0 resection and residual liver lesions were also resected. After 3 months, a tumor relapsed in the liver. She was then treated with olaparib combined with pembrolizumab and achieved stable disease on the liver lesion. The patient eventually died from cerebral hemorrhage with a long OS of 21 months. Our case demonstrated a favorable clinical activity and survival advantage of the combined cisplatin and nanoparticle albumin-bound paclitaxel, which might serve as a therapeutic option for the patient with BRCA-mutant pancreatic SCC.https://www.frontiersin.org/articles/10.3389/fonc.2021.585983/fullpancreatic squamous cell carcinomacisplatinnanoparticle albumin-bound paclitaxelBRCA2 mutationoverall survival |
| spellingShingle | Xiaozhun Huang Chunling Wang Teng Ma Zhangkan Huang Houhong Zhou Lin Xu Renjie Zhang Jianjun Zhao Yefan Zhang Zhen Huang Lin Shao Yang Wang Fan Yang Xu Che Xu Che The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report Frontiers in Oncology pancreatic squamous cell carcinoma cisplatin nanoparticle albumin-bound paclitaxel BRCA2 mutation overall survival |
| title | The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report |
| title_full | The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report |
| title_fullStr | The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report |
| title_full_unstemmed | The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report |
| title_short | The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report |
| title_sort | efficacy of combined cisplatin and nanoparticle albumin bound paclitaxel in a stage iv pancreatic squamous cell carcinoma patient with a somatic brca2 mutation a case report |
| topic | pancreatic squamous cell carcinoma cisplatin nanoparticle albumin-bound paclitaxel BRCA2 mutation overall survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.585983/full |
| work_keys_str_mv | AT xiaozhunhuang theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT chunlingwang theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT tengma theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT zhangkanhuang theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT houhongzhou theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT linxu theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT renjiezhang theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT jianjunzhao theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT yefanzhang theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT zhenhuang theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT linshao theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT yangwang theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT fanyang theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT xuche theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT xuche theefficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT xiaozhunhuang efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT chunlingwang efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT tengma efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT zhangkanhuang efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT houhongzhou efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT linxu efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT renjiezhang efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT jianjunzhao efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT yefanzhang efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT zhenhuang efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT linshao efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT yangwang efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT fanyang efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT xuche efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport AT xuche efficacyofcombinedcisplatinandnanoparticlealbuminboundpaclitaxelinastageivpancreaticsquamouscellcarcinomapatientwithasomaticbrca2mutationacasereport |